ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the…

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to complete enrollment in Q3 2026The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.Current…